11 Biotechnology Stocks to Buy Now

Advertisement

This week, 11 biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Idera Pharmaceuticals, Inc. (IDRA) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Idera Pharmaceuticals is engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like Receptors (TLRs) to treat infectious diseases, autoimmune and inflammatory diseases, cancer, asthma and allergies, and for use as vaccine adjuvants. In Portfolio Grader’s specific subcategory of Sales Growth, IDRA also gets an A. For more information, get Portfolio Grader’s complete analysis of IDRA stock.

Mirati Therapeutics Inc. (MRTX) gets a higher grade this week, advancing from a C last week to a B. Mirati Therapeutics engages in the development of therapeutics for the treatment of cancer. For more information, get Portfolio Grader’s complete analysis of MRTX stock.

This week, Ophthotech Corp. (OPHT) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. For more information, get Portfolio Grader’s complete analysis of OPHT stock.

MediciNova, Inc. (MNOV) earns an A this week, jumping up from last week’s grade of B. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

This is a strong week for BioTime, Inc. (BTX). The company’s rating climbs to B from the previous week’s C. BioTime is a biotechnology company that focuses on regenerative medicine and blood plasma volume expanders. For more information, get Portfolio Grader’s complete analysis of BTX stock.

Novavax, Inc. (NVAX) gets a higher grade this week, advancing from a C last week to a B. Novavax creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle technology. For more information, get Portfolio Grader’s complete analysis of NVAX stock.

La Jolla Pharmaceutical Company (LJPC) is seeing ratings go up from a B last week to an A this week. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

The rating of Medgenics, Inc. (MDGN) moves up this week, rising from a C to a B. Medgenics is a biopharmaceutical company that develops therapeutic protein delivery technology for the treatment of a range of chronic diseases. For more information, get Portfolio Grader’s complete analysis of MDGN stock.

This week, Ambit Biosciences Corp. (AMBI) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Gilead Sciences, Inc. (GILD) earns an A this week, jumping up from last week’s grade of B. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of GILD stock.

This is a strong week for AMAG Pharmaceuticals, Inc. (AMAG). The company’s rating climbs to A from the previous week’s B. AMAG Pharmaceuticals utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. For more information, get Portfolio Grader’s complete analysis of AMAG stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/01/11-biotechnology-stocks-to-buy-now-idra-mrtx-opht/.

©2024 InvestorPlace Media, LLC